CEACAM5 and neoplasm: For example, a recombinant yeast-CEA vaccine was previously used in vitro to efficiently activate murine and human T cells that were lytic against CEA-expressing targets, and in vivo for vaccination of tumor-bearing mice resulting in anti-tumor activity.